New birth-control options, including free injectable contraceptives, have long been advocated by international organizations, among them the U.S. Agency for International Development and the Bill & Melinda Gates Foundation.
MAHENDRAGARH, India — This is what family planning in India often looks like: Women in their 20s, mostly farmers’ wives, gather at dawn on the stairs of a district hospital. Hours later, a surgeon arrives. His time is short. He asks the women to sit in a row on the floor of the operating room and then, in surgeries lasting a few minutes apiece, uses a laparoscope to sever their fallopian tubes, ensuring they will never again bear a child.
For decades, India has relied on female sterilization as its primary mode of contraception, paying for about 4 million tubal ligations every year, more than any other country. This year, the government of Prime Minister Narendra Modi will take a major step toward modernizing that system, introducing injectable contraceptives for free in government facilities. The World Health Organization (WHO) recommends their use without restriction for women of childbearing age.
New birth-control options have long been advocated by international organizations, among them the U.S. Agency for International Development and the Bill & Melinda Gates Foundation. They say Indian women — often worn out, anemic and at higher risk of death because they bear children young and often — urgently need methods to delay or space pregnancies.
India will soon surpass China as the world’s most populous nation; by 2050, it is expected to gain 400 million new citizens, more than the population of the United States.
Most Read Stories
- 'I'm amazed tourists ever come back': Your comments on Seattle's poor tourism survey
- Nathan Hale's Michael Porter Jr. asks for release from Washington
- Rare, often fatal, respiratory disease carried by mice — hantavirus — confirmed in King County
- AP Exclusive: Before Trump job, Manafort worked to aid Putin VIEW
- Measles cases in South Lake Union: Were you exposed?
Paradoxically, in India, the keenest opposition to these newer methods of birth control — ones seen in the West as empowering women to control their fertility — has come from some women’s activist groups that distrust the safety of these methods and believe that profit-hungry Western pharmaceutical companies are pushing them. Despite growing evidence of the safety of the injectables and their increasingly widespread use across South Asia, these groups have continued to oppose them. And it is Modi’s socially conservative Bharatiya Janata Party that has broken with decades of resistance to injectables.
The shift in policy has come in part because the government is less concerned about opposition from civil-society groups, most of them more closely aligned with the previous ruling party, the Indian National Congress. Officials were also spurred by a medical disaster in the Indian state of Chhattisgarh, where 13 women died in 2014 after undergoing tubal ligation at a high-volume government “sterilization camp.”
“I thought it was incumbent on the government to provide it as a choice,” C.K. Mishra, additional secretary in the Ministry of Health and Family Welfare, said of the contraceptive Depot medroxyprogesterone acetate, or DMPA, which has been used in the private sector since 1993. Still, the method will be introduced gingerly, limited at first to select district hospitals and medical colleges and then expanded next year to hospitals throughout the country. Implanted contraceptives may follow.
“We want to be very careful,” Mishra said.
Distrust by critics
In the context of India’s recent history, it is no wonder officials have been risk-averse and advocates mistrustful. In 1975, the government of Prime Minister Indira Gandhi led an aggressive campaign, in some cases forcing young or childless men to undergo vasectomies to meet quotas. More than 6 million sterilizations were performed, igniting a widespread protest movement.
More than a decade later, when India began exploring the public use of injectable contraceptives, activist groups filed cases with the country’s Supreme Court seeking to ban the drugs.
The court forwarded the matter to India’s Drug Technical Advisory Board, which in 1995 allowed private use to continue but recommended against offering them in government clinics. The decision was not revisited for 20 years, even as use of the method became widespread in neighboring Bangladesh, Sri Lanka and Nepal.
Opponents contend India’s health infrastructure is too weak to regulate use of the drugs, monitor side effects or ensure that patients have given informed consent. India’s government spends about 1 percent of its gross domestic product on public health, compared with about 3 percent in Russia and China and 8 percent in the United States.
“Invariably these new methods are tried on women who have no infrastructure to fall back on, who have no other resources,” said Navsharan Singh, a senior program specialist at the International Development Research Center, which is financed by the government of Canada. She said the current plan, to deliver the drugs through major hospitals, improved the prospects for follow-up.
Some opposition is tinged with ideology, with critics tracing U.S. support for population control back to a Cold War era when they say birth control was seen as a way to stop the spread of Communism by curbing chronic poverty.
The atmosphere around injectable contraceptives began to shift after Modi’s party took over in May 2014, and it gained momentum after the Chhattisgarh catastrophe, about six months later. Last year, “All the stars aligned,” said Dr. Jyoti Vajpayee, a gynecologist who oversees family-planning programs here for the Gates Foundation. “This government has come back in a majority, so they can afford to take risks,” she said.
She and others had long sought to convince officials that existing options — male and female sterilization, the pill, IUDs and condoms — were insufficient for millions of Indian women who marry in their late teens and spend years carrying back-to-back pregnancies.
Research has shown that, globally, 30 percent of maternal deaths and 10 percent of child deaths could be prevented if women spaced their pregnancies two years apart.
In August, the Drug Technical Advisory Board recommended that DMPA be included in the family-planning program, saying 20 years of private use and studies of similar drugs by the Indian Council for Medical Research had established they were safe to introduce without a pilot program.
Dr. C.N. Purandare, past president of the Federation of Obstetric and Gynecological Societies of India and a proponent of the drugs, praised the government for what he called “a bold step.”
Not that the traditional method is being phased out. At a recent sterilization camp about 90 miles west of Delhi, a time-honored system was chugging along.
The women here, many of whom had traveled from their villages, said that they were eager to go for “the operation,” and that the cash incentive of 1,400 rupees, about $20, had not affected their decision. They had been urged on by outreach workers who had accompanied them to the camp, older women from their own villages.
These women are paid 1,000 rupees for each patient with two or fewer children who comes in for sterilization, and 240 rupees for each patient with three or more. They admitted that there were drawbacks to sterilization, especially for young women who might someday want to have another child.
“We have to tell them a lot of things to convince them,” said Sudesh Wati, 50.
Asked about injectable contraceptives, the women mostly looked blank. They had never heard of them.
In any case, said Lalit Sharma, a nurse who trains outreach workers, when a new method comes online, women will almost certainly accept it. “Whatever method it might be,” he said, “if the government implements it, they blindly trust it.”